A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections
Phase of Trial: Phase IV
Latest Information Update: 19 Jul 2017
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial skin diseases
- Focus Therapeutic Use
- Acronyms ABSSSI
- Sponsors Allergan
- 13 Jul 2017 Planned End Date changed from 1 Sep 2017 to 30 Jun 2018.
- 13 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Jun 2018.
- 09 Dec 2016 Status changed from not yet recruiting to recruiting.